#1 Clinical Trials Search in Europe

Cariprazine Hydrochloride

Cariprazine Hydrochloride, also known as MP-214 or RGH-188, is a medication being studied in clinical trials for its potential to treat various mental health conditions. This article explores the use of Cariprazine in clinical trials for schizophrenia, bipolar disorder, and autism spectrum disorder, highlighting its safety, efficacy, and long-term effects.

Table of Contents

What is Cariprazine?

Cariprazine Hydrochloride, also known by its brand name Vraylar or research codes MP-214 and RGH-188, is a medication used to treat various mental health conditions[1][2]. It belongs to a class of drugs called atypical antipsychotics, which are newer medications designed to treat psychotic disorders with potentially fewer side effects than older antipsychotic drugs.

Conditions Treated by Cariprazine

Cariprazine is primarily used to treat the following conditions:

  • Schizophrenia: A serious mental disorder that affects a person’s thinking, emotions, and behavior[1]
  • Bipolar I Disorder: A mood disorder characterized by alternating episodes of mania and depression[2]
  • Bipolar Depression: The depressive phase of bipolar disorder[2]
  • Autism Spectrum Disorder (ASD): A developmental disorder that affects communication and behavior[5]

How Cariprazine Works

Cariprazine works by affecting certain chemicals in the brain, primarily dopamine and serotonin. It is particularly known for its action on the D3 dopamine receptor, which is thought to play a role in mood regulation and cognitive function[3]. This unique mechanism of action may contribute to its effectiveness in treating both schizophrenia and bipolar disorder.

Dosage and Administration

Cariprazine is typically taken orally, usually once daily. The dosage can vary depending on the condition being treated, the patient’s age, and other factors[1][2]. Some key points about dosing include:

  • For adults with schizophrenia or bipolar disorder, doses may range from 1.5 mg to 6 mg per day
  • In some studies, doses up to 12.5 mg per day have been investigated[1]
  • For pediatric patients, dosing is typically based on age and body weight[5]
  • The medication may be started at a lower dose and gradually increased to find the most effective dose with minimal side effects

It’s important to take cariprazine exactly as prescribed by your healthcare provider.

Efficacy Studies

Several clinical trials have been conducted to evaluate the effectiveness of cariprazine:

  • Schizophrenia: Studies have shown improvements in symptoms as measured by the Positive and Negative Syndrome Scale (PANSS), which assesses the severity of schizophrenia symptoms[4][6]
  • Bipolar Depression: Research has demonstrated improvements in depressive symptoms using the Montgomery-Asberg Depression Rating Scale (MADRS)[2]
  • Overall Improvement: Many studies have used the Clinical Global Impression (CGI) scales to assess overall improvement in patients’ conditions[2][4]

Safety and Side Effects

As with all medications, cariprazine can cause side effects. Common side effects may include[1][5]:

  • Restlessness or feeling the need to move (akathisia)
  • Weight gain
  • Digestive issues
  • Drowsiness

More serious side effects, though less common, can include:

  • Changes in blood sugar or cholesterol levels
  • Abnormal movements (tardive dyskinesia)
  • Changes in heart rhythm

Your healthcare provider will monitor you for these and other potential side effects during treatment.

Long-Term Use of Cariprazine

Studies have been conducted to assess the long-term safety and efficacy of cariprazine. These studies, lasting up to 48 weeks, have shown that cariprazine can be effective for long-term management of schizophrenia and bipolar disorder[4][6]. However, as with any long-term medication use, regular check-ups with your healthcare provider are important to monitor for any potential issues.

Cariprazine in Pediatric Patients

Research is ongoing to evaluate the use of cariprazine in children and adolescents with schizophrenia, bipolar disorder, and autism spectrum disorder[5]. These studies are assessing the safety, efficacy, and appropriate dosing for younger patients. If you’re considering cariprazine for a child or adolescent, it’s crucial to discuss the potential benefits and risks with a healthcare provider experienced in pediatric mental health.

Aspect Details
Conditions Studied Schizophrenia, Bipolar I Disorder, Bipolar Depression, Autism Spectrum Disorder
Age Groups Adults and Pediatric (ages 5-17, depending on condition)
Dosage Range 0.25 mg to 12.5 mg daily, flexible dosing based on condition and body weight
Administration Oral capsules or solution, taken once daily
Study Durations 14 days to 52 weeks
Primary Outcomes Safety, tolerability, efficacy (measured by symptom rating scales)
Secondary Outcomes Pharmacokinetics, changes in clinical global impression scales
Safety Monitoring Adverse events, laboratory parameters, vital signs, movement disorders, suicidal ideation
Efficacy Measures PANSS, MADRS, CGI-S, CGI-I scales

FAQ

  • What conditions is Cariprazine being studied for in clinical trials? Cariprazine is being studied for the treatment of schizophrenia, bipolar I disorder (including bipolar depression), and autism spectrum disorder (ASD).
  • What are the typical dosages of Cariprazine used in clinical trials? Clinical trials have explored various dosages, ranging from 0.25 mg to 12.5 mg per day, depending on the condition being treated and the specific study design.
  • How long do Cariprazine clinical trials typically last? The duration of clinical trials varies, with some studies lasting for 14 days, while others extend up to 52 weeks to assess long-term safety and efficacy.
  • What are some of the primary outcomes measured in Cariprazine clinical trials? Primary outcomes often include changes in symptom severity scales such as the Positive and Negative Syndrome Scale (PANSS) for schizophrenia, Montgomery-Asberg Depression Rating Scale (MADRS) for bipolar depression, and assessments of adverse events and tolerability.
  • Are there any specific safety concerns being monitored in Cariprazine clinical trials? Yes, clinical trials closely monitor for adverse events, changes in laboratory parameters, vital signs, and specific side effects such as akathisia, tardive dyskinesia, and changes in metabolic parameters.

Ongoing Clinical Trials on Cariprazine Hydrochloride

  • Study on the Effectiveness and Safety of Cariprazine for Adolescents (13-17 years) with Schizophrenia

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Romania

  • Study on the Safety and Tolerability of Cariprazine for Treating Schizophrenia in Adolescents Aged 13-17

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Germany Romania

Glossary

  • Cariprazine Hydrochloride: A medication being studied for the treatment of various mental health disorders, including schizophrenia, bipolar disorder, and autism spectrum disorder.
  • Schizophrenia: A chronic mental disorder characterized by distortions in thinking, perception, emotions, language, sense of self, and behavior.
  • Bipolar I Disorder: A mental health condition characterized by alternating episodes of mania and depression.
  • Autism Spectrum Disorder (ASD): A developmental disorder that affects communication and behavior, with a wide range of symptoms and severity.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Positive and Negative Syndrome Scale (PANSS): A medical scale used to measure symptom severity in patients with schizophrenia.
  • Montgomery-Asberg Depression Rating Scale (MADRS): A ten-item diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders.
  • Clinical Global Impression (CGI) Scale: A tool used by healthcare professionals to assess the overall severity and improvement of a patient's mental illness.
  • Adverse Event: Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Akathisia: A movement disorder characterized by a feeling of inner restlessness and inability to stay still.
  • Tardive Dyskinesia: A side effect of some antipsychotic medications, characterized by involuntary, repetitive body movements.

References

  1. https://clinicaltrials.gov/study/NCT00862992
  2. https://clinicaltrials.gov/study/NCT00852202
  3. https://clinicaltrials.gov/study/NCT05060549
  4. https://clinicaltrials.gov/study/NCT01104792
  5. https://clinicaltrials.gov/study/NCT04578756
  6. https://clinicaltrials.gov/study/NCT00839852